Rheumatoid Arthritis in the Russian Federation According to Russian Arthritis Registry Data (Communication I)

Nasonov, E.; Karateev, D. E.; Сатыбалдыев, А. М.; Лучихина, Е. Л.; Lukina, G. V.; Николенко, Н. В.; Bilinskaya, V. A.; Дмитриева, М. Е.; Bogoderova, L. A.; Lapkina, N. A.; Chichasova, N. V.; Sorotskaya, V.; Abdulganieva, D. I.; Mukhina, R. G.; Gafurov, G. R.; Mazurov, V. I.; Chakieva, D. S.; Samigullina, R. R.; Кузнецова, Е. Г.; Demidova, N. V.; Никишина, Н. Ю.; Федоренко, Е. В.; Gerasimova, E.; Zlepko, E. A.; Muravyeva, N. V.; Gridneva, G. I.; Rumyantseva, O.; Kasumova, K. A.; Alekseeva, A. V.; Шорникова, Н. С.; Владимиров, С. А.; Gukasyan, D. A.; Tyurina, L. N.; Denisov, L. N.; Oskilko, T. G.; Koshkarova, E. A.

doi:10.14412/1995-4484-2016-50-62

rsp

2016

DOI: 10.14412/1995-4484-2016-50-62

|View full text |Cite

Rheumatoid Arthritis in the Russian Federation According to Russian Arthritis Registry Data (Communication I)

E. Nasonov¹,

D. E. Karateev²,

А. М. Сатыбалдыев³

et al.

Abstract: Представлены материалы Российского регистра больных артритом (ОРЕЛ). В регистр включено 3276 пациен-тов из 11 крупнейших научно-практических центров Российской Федерации, расположенных в Москве, Санкт-Петербурге, Новосибирске, Казани, Туле, Ярославле, Тюмени. Обсуждаются основные цели создания регистров, сопоставляются результаты анализа данных Российского регистра ОРЕЛ и регистров стран Евро-пы и США. Полученные данные свидетельствуют о неоднородности информации о клинических, лаборатор-ных и инструментальных… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 The registry demonstrates a significant prevalence of RA in city residents over rural, although this may also be associated with the concentration of rheumatologic care centers in big cities, and their limited availability in the villages. Moreover, the OREL registry includes fewer smokers compared to other registries from European countries and the United States, and contains the most detailed information on comorbidities, 14 which prevent improvements in the quality of life during RA treatment by DMARDs. 22 The registry helps to identify groups of patients with variable disease courses and develop specific treatment protocols for each geographical region.…”

mentioning

confidence: 99%

“…Additionally, a special program for the education of nurses with backgrounds in rheumatology has been developed. 14 Another approach to improve RA treatment is an original method of Structured Programs for RA patients, involving training for patients to self-evaluate their disease activity by counting the number of tender and swollen joints between visits to the doctor. 23 Starting in 2000, Russia has conducted multicentral placebo-controlled clinical studies of new antirheumatic drugs in collaboration with leading pharmaceutical companies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Current and future trends in Russian Rheumatology Care and Research

Tchetina¹

2017

MJR

View full text Add to dashboard Cite

This short article provides a description of the present state of rheumatology care and research in Russia and discusses opportunities for development and cooperation. Rheumatic diseases (RDs) in Russia represent the second most common pathology after cardiovascular disorders. Although RDs include more than 200 diseases and syndromes, the most common in Russia are osteoarthritis (OA), rheumatoid arthritis (RA), gout, and low back pain, largely similar to those seen in most Western societies. Interestingly, the prevalence of RA appears to have increased from 0.42% to 1% in the Russian population since the last large-scale epidemiologic study, which was conducted 25 years ago in the former USSR; this is an opposite trend to that seen in most Western countries 1 and is similar to other reports that have indicated that RA prevalence has risen in Europe and North America due to the underlying aging population 2 and increasing patient survival. 3 This would be interesting to study in comparative collaborative research. Approximately 10% of the Russian population is presently affected by RDs. 4 The major factors responsible for the increased prevalence of RDs in Russia include increased mutation activity associated with environmental pollution and an augmented incidence of concomitant disorders such as obesity, diabetes mellitus, hypertension, and others. Recent large epidemiologic study including 76,000 subjects from 18 regions of the Russian Federation revealed that statistical indices are significantly lower (up to 5-fold) than real prevalence of RDs among adults registered according to the attendance in clinics. 5 Besides, individual federal regions demonstrate different dynamics. For example, in Central Russia, the incidence of almost all RDs excluding osteoporosis decreased, while in the Western region, an increase in the incidence of RA and OA during one year of follow-up was observed. 6 Russia is a large territory and has a multinational population. This provides the opportunity to study different disease subtypes and phenotypes associated with genetic variability, national psychological traits, various climates, ecological conditions, and environmental factors. However, all these possibilities are limited by the insufficient funding of rheumatic research. Therefore, such type of research is a subject for future studies. Recently, Russia is developing a three-level standardized system for management of RD patients involving primary medical care, specialized treatment protocols, and rehabilitation technologies developed by the leading rheumatologic centers. Russia has great tradition in rehabilitation. Recent studies on combination of "treat to target" therapies with concomitant rehabilitation program have demonstrated that this approach is more efficient than pharmacological therapy alone primarily for early RA patients. It involves

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Current and future trends in Russian Rheumatology Care and Research

Tchetina¹

2017

MJR

View full text Add to dashboard Cite

show abstract

Strategy for Development of Rheumatology: From Scientific Achievements to Practical Healthcare

Nasonov

Лила²,

Галушко³

et al. 2017

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)

Doktorova,

Grabovetskaya,

Stefanov

et al. 2024

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

INTRODUCTION. Methotrexate (MTX) is the main disease-modifying antirheumatic drug (DMARD) and the gold standard for the safety and efficacy evaluation of biologicals and targeted small molecules. However, its narrow therapeutic range, interpatient variability in pharmacokinetics and pharmacodynamics, and potential clinically relevant drug–drug interactions (DDIs) may lead to treatment failure and increase the risk of adverse drug reactions (ADRs).AIM. The study aimed to describe the main clinically significant DDIs associated with MTX used in rheumatic disease therapy and determine possible approaches to addressing this issue based on a literature review.DISCUSSION. MTX is characterised by pharmacokinetic DDIs during absorption, cell penetration, and elimination. Some non-steroidal anti-inflammatory drugs (NSAIDs), theophylline, sulfasalazine, antibacterial agents, and proton pump inhibitors (PPIs) affect MTX elimination and therapeutic effects. The main ADRs associated with MTX include haematotoxicity, hepatotoxicity, lung tissue damage (interstitial pneumonitis and pulmonary fibrosis), and renal dysfunction. The severity of these ADRs depends on the dose, comorbidities, and concomitant therapy. The toxicity of MTX may be increased by the concomitant administration of medicinal products that exhibit haematotoxicity and affect renal function (impair the elimination of medicines). When co-administering MTX and medicines having clinically significant DDIs described in the literature, healthcare providers should consider the risk factors for each individual patient. The most significant risk factors include moderate to severe renal and hepatic impairment, older age, polypharmacy, and hypoalbuminemia.CONCLUSIONS. This article describes potential clinically significant interactions between MTX and certain NSAIDs, antibacterial agents, and PPIs that depend on individual patient characteristics and may increase the toxicity or decrease the effectiveness of MTX. MTX deprescribing, short-term withdrawal, and dosing optimisation may be considered as approaches to DDI risk mitigation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rheumatoid Arthritis in the Russian Federation According to Russian Arthritis Registry Data (Communication I)

Cited by 3 publications

References 62 publications

Current and future trends in Russian Rheumatology Care and Research

Current and future trends in Russian Rheumatology Care and Research

Strategy for Development of Rheumatology: From Scientific Achievements to Practical Healthcare

Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)

Contact Info

Product

Resources

About